Abzyme Therapeutics is a biopharmaceutical discovery and service company with expertise in modular antibody discovery and conditionally-active antibody engineering for immunotherapy using proprietary antibody generation and optimization platforms. The company is located in the Philadelphia biotechnology/pharmaceutical hub.
Unique to Abzyme is our proprietary and highly engineered eukaryotic in vitro antibody discovery/optimization platform based on yeast-display, self-diversifying libraries, rapid target-directed antibody affinity maturation in combination with a FACS single-cell sorting approach to identify desired antibodies. Abzyme’s modular antibody discovery platform incorporates real-time screening ability to select for key properties such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity.
Today, the Company has over 60 proprietary and partnered programs in development in therapeutic and diagnostic areas including infectious diseases, immuno-oncology, ophthalmology, inflammation and central nervous system disorders.